Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility

Daniel L Hertz; James M Rae

doi:10.1158/1078-0432.CCR-16-0370

Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility

Clin Cancer Res. 2016 Jul 1;22(13):3121-3. doi: 10.1158/1078-0432.CCR-16-0370. Epub 2016 Mar 24.

Authors

Daniel L Hertz¹, James M Rae²

Affiliations

¹ Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan. [email protected].
² Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.

Abstract

Tamoxifen may require metabolic activation to endoxifen for efficacy in treating hormone receptor-positive breast cancer. Dose escalation in patients with low endoxifen concentrations could enhance treatment efficacy. This approach is clinically feasible, and successfully increases endoxifen concentrations; however, it is unknown whether patients benefit from individualized tamoxifen dose escalation. Clin Cancer Res; 22(13); 3121-3. ©2016 AACRSee related article by Fox et al., p. 3164.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents, Hormonal / administration & dosage
Antineoplastic Agents, Hormonal / therapeutic use*
Breast Neoplasms / drug therapy*
Drug Dosage Calculations
Female
Humans
Tamoxifen / administration & dosage*
Tamoxifen / analogs & derivatives*
Tamoxifen / metabolism
Tamoxifen / therapeutic use*

Substances

Antineoplastic Agents, Hormonal
Tamoxifen
4-hydroxy-N-desmethyltamoxifen

Grants and funding

R01 GM099143/GM/NIGMS NIH HHS/United States